Ardelyx Inc Logo Image

Ardelyx Inc

Most Recent Annual Report

2015 Annual Report and Form 10K

Ardelyx Inc

Ardelyx Inc does not currently have any hardcopy reports available on AnnualReports.com. Click the button below to be notified when hardcopies become available.



Archived Annual Reports

  • Ardelyx Inc

About Ardelyx Inc

51-200 Employees
Based in Fremont, California

Ardelyx, Inc. discovers, develops, and commercializes minimally-systemic small molecule therapeutics for the gastrointestinal (GI) tract to treat cardio-renal, GI, and metabolic diseases. Its lead product candidate is tenapanor, a small molecule NHE3 inhibitor, which has completed Phase 2b clinical trial for the treatment of patients with constipation-predominant irritable bowel syndrome and hyperphosphatemic patients with chronic kidney disease on dialysis, as well as Phase 2a clinical trial in patients with late-stage chronic kidney disease.

Ticker:
ARDX
Exchange:
NASDAQ (See More NASDAQ Companies)
Industry:
Biotechnology (See More Biotechnology Companies)
Sector:
Healthcare (See More Healthcare Companies)

Looking for Other Annual Reports?

Search by company name or ticker symbol